Tenax Therapeutics Net Worth

Tenax Therapeutics Net Worth Breakdown

  TENX
The net worth of Tenax Therapeutics is the difference between its total assets and liabilities. Tenax Therapeutics' net worth represents the value of the company's equity or ownership interest. In other words, it is the amount of money that would be left over if all of Tenax Therapeutics' assets were sold and all of its debts were paid off. Net worth is sometimes referred to as shareholder's equity or book value. Tenax Therapeutics' net worth can be used as a measure of its financial health and stability which can help investors to decide if Tenax Therapeutics is a good investment. It is also essential in determining the company's creditworthiness and ability to secure financing before investing in Tenax Therapeutics stock.

Tenax Therapeutics Net Worth Analysis

Tenax Therapeutics' net worth analysis, or its valuation, is the process of determining the total value of the company. This involves assessing a range of factors, including Tenax Therapeutics' financial performance, assets, liabilities, and potential for growth. The ultimate goal is to provide a clear understanding of Tenax Therapeutics' overall worth, which can help investors make informed investment decisions. There are several methods that can be used to perform Tenax Therapeutics' net worth analysis. One common approach is to calculate Tenax Therapeutics' market capitalization.Another approach is to use the price-to-earnings ratio (P/E ratio), which compares Tenax Therapeutics' stock price to its earnings per share (EPS). Discounted cash flow (DCF) analysis is another popular method for assessing Tenax Therapeutics' net worth. This approach calculates the present value of Tenax Therapeutics' future cash flows, taking into account factors such as growth rate, profitability, and risk. By comparing the present value of Tenax Therapeutics' cash flows to its current stock price, investors can gain a better understanding of the company's overall value. Finally, investors may use comparable company analysis to evaluate Tenax Therapeutics' net worth. This involves comparing Tenax Therapeutics' financial metrics to similar companies in the same industry. By identifying companies with similar financial characteristics, investors can gain insight into Tenax Therapeutics' net worth relative to its peers.
To determine if Tenax Therapeutics is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Tenax Therapeutics' net worth research are outlined below:
Tenax Therapeutics had very high historical volatility over the last 90 days
Tenax Therapeutics has high likelihood to experience some financial distress in the next 2 years
Net Loss for the year was (7.71 M) with profit before overhead, payroll, taxes, and interest of 0.
Tenax Therapeutics currently holds about 7.23 M in cash with (5.9 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.29.
Tenax Therapeutics uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Tenax Therapeutics. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Tenax Therapeutics' previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
12th of February 2024
Upcoming Quarterly Report
View
20th of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
12th of February 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

Follow Tenax Therapeutics' market capitalization trends

The company currently falls under 'Micro-Cap' category with a current market capitalization of 24.78 M.
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Tenax Therapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Tenax Therapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Tenax Therapeutics insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
 
Dellora Investments Lp over two months ago
Insider Trading
 
Armistice Capital, Llc over two months ago
Acquisition by Armistice Capital, Llc of tradable shares of Tenax Therapeutics subject to Rule 16b-3
 
Christopher Giordano over two months ago
Acquisition by Christopher Giordano of 1250000 shares of Tenax Therapeutics at 5.94 subject to Rule 16b-3
 
Almenoff June Sherie over three months ago
Acquisition by Almenoff June Sherie of 100000 shares of Tenax Therapeutics at 5.94 subject to Rule 16b-3
 
Mcgauley Thomas over three months ago
Insider Trading
 
Rich Stuart over three months ago
Acquisition by Rich Stuart of 100000 shares of Tenax Therapeutics at 0.62 subject to Rule 16b-3
 
Davidson Michael H. over three months ago
Acquisition by Davidson Michael H. of 47500 shares of Tenax Therapeutics at 0.01 subject to Rule 16b-3
 
Davidson Michael H. over six months ago
Acquisition by Davidson Michael H. of 25000 shares of Tenax Therapeutics at 4.5 subject to Rule 16b-3
 
Davidson Michael H. over six months ago
Acquisition by Davidson Michael H. of 2500 shares of Tenax Therapeutics at 3.0 subject to Rule 16b-3
 
Armistice Capital, Llc over six months ago
Acquisition by Armistice Capital, Llc of 4773269 shares of Tenax Therapeutics at 1.0E-4 subject to Rule 16b-3
 
Rich Stuart over six months ago
Acquisition by Rich Stuart of 3581000 shares of Tenax Therapeutics subject to Rule 16b-3
 
Armistice Capital, Llc over six months ago
Discretionary transaction by Armistice Capital, Llc of 3175924 shares of Tenax Therapeutics at 0.903 subject to Rule 16b-3
Tenax Therapeutics time-series forecasting models is one of many Tenax Therapeutics' stock analysis techniques aimed to predict future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Tenax Therapeutics' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.

Tenax Therapeutics Earnings per Share Projection vs Actual

Tenax Therapeutics Corporate Management

Doug RandallExecutive VP of Commercial and Bus. OperationsProfile
Eliot CPAInterim OfficerProfile
Nancy HecoxGen AffairsProfile
Esq CPAInterim OfficerProfile

Additional Tools for Tenax Stock Analysis

When running Tenax Therapeutics' price analysis, check to measure Tenax Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Tenax Therapeutics is operating at the current time. Most of Tenax Therapeutics' value examination focuses on studying past and present price action to predict the probability of Tenax Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Tenax Therapeutics' price. Additionally, you may evaluate how the addition of Tenax Therapeutics to your portfolios can decrease your overall portfolio volatility.